<DOC>
	<DOCNO>NCT00679068</DOCNO>
	<brief_summary>Bosentan largely use treatment pulmonary hypertension ( PH ) . It improve exercise capacity , low Borg dyspnoea score nad effect usually associate concomitant improvement cardiopulmonary haemodynamics . No physiological study far verified hypothesis Bosentan may laso effect `` respiratory side '' cadio-pulmonary system ( i.e . pulmonary mechanic work breathe )</brief_summary>
	<brief_title>Effects Bosentan Respiratory Mechanics</brief_title>
	<detailed_description>Endothelins powerful vasoconstrictor peptide also play numerous function many different organ . Endothelin-1 ( ET-1 ) abundant important family peptide blood vessel . Production ET-1 increase endothelium kidney salt-dependent model hypertension ET-1 elicit inflammatory response increase oxidant stress vascular wall , induces vascular remodel endothelial dysfunction find hypertensive model exhibit endothelin-mediated component . Endothelin receptor antagonist low blood pressure hypertensive patient . They could become therapeutic agent prevention target organ damage hypertension type 2 diabetes , chronic renal failure congestive heart failure . Side effect endothelin receptor blocker prevent present development indication . Endothelin antagonists approve treatment pulmonary hypertension , rapidly fatal condition endothelin system play important role endothelin antagonists exert favorable effects.The exact mechanism action ERAs pulmonary vascular bed remain unclear . Vasodilatation part mechanism , since usually 70 % -80 % Idiopathic PAH patient respond acutely vasodilator . Endothelin likely involve pulmonary vasoconstriction , inflammation , cellular proliferation fibrosis ie . remodelling Recent research illustrate bosentan capable blunt vascular remodelling normally associate PAH If ERAs could prevent remodelling , might substantially improve long-term survival patient mild symptom ( WHO class II I ) . Bosentan , popular endothelin receptor antagonist , largely used treatment pulmonary hypertension ( PH ) . It improve exercise capacity , low Borg dyspnoea score nad effect usually associate concomitant improvement cardiopulmonary haemodynamics . No physiological study far verified hypothesis Bosentan may laso effect `` respiratory side '' cadio-pulmonary system ( i.e . pulmonary mechanic work breathe )</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Adult patient World Health Organization ( WHO ) functional class IIIII . A systemic pulse oximetry ( SpO2 ) 70 % 90 % rest room air baseline 6minute walk distance 150 450 require inclusion . PAH confirm cardiac catheterization mean pulmonary arterial pressure great equal to25 mm Hg , pulmonary capillary wedge pressure low 15 mm Hg , Patients exclude patent ductus arteriosus ( hemodynamic assessment difficulty ) complex congenital heart defect leave ventricular dysfunction ( left ventricular ejection fraction lower 40 % ) restrictive lung disease ( total lung capacity lower 70 % predict ) obstructive lung disease ( forced expiratory volume 1 second [ FEV1 ] low 70 % predict FEV1/forced vital capacity lower 60 % ) previously diagnose coronary artery disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>respiratory mechanic</keyword>
	<keyword>bosentan</keyword>
	<keyword>exercise capacity</keyword>
</DOC>